CTLA4 and neoplasm: Although previous studies demonstrated that anti-CTLA-4 therapy required Fc effector functions for the anti-tumor efficacy [11–14, 16], the data presented here, to our knowledge, revealed for the first time in preclinical syngeneic tumor models an Fc-independent mechanism for inducing anti-tumor immunity following treatment with anti-CTLA-4 modalities.